Home › Forums › Other Specialities › Therapeutics › DEXAMETHASONE IN COVID 19.
- This topic has 0 replies, 1 voice, and was last updated 10 months, 3 weeks ago by Anonymous.
-
AuthorPosts
-
-
December 21, 2023 at 1:45 pm #2708AnonymousInactive
ORIGINAL ARTICLE
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary ReportFirst publication
The RECOVERY Collaborative Group*
BACKGROUND
Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.METHODS
In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone.The primary outcome was 28-day mortality. Here, we report the preliminary results of this comparison.
Overall, the study found that dexamethasone reduced mortality by 17%, adjusted for age.
RESULTS
A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care.Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001).
The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization.
In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.91 to 1.55).
CONCLUSIONS
In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.New England JOURNAL OF MEDICINE
-
-
AuthorPosts
- You must be logged in to reply to this topic.